Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Jorik van Rijn

Postdoc

Hunting for new immunotherapy targets in pediatric T-cell leukemia

For one in five children with T-cell acute lymphoblastic leukemia (T-ALL), the current chemotherapy treatment is not effective. For those relapsed/refractory patients, no other curative treatments now exist. My primary goal is to develop a new therapy for these high-risk T-ALL patients based on the recently successful Chimeric Antigen Receptor (CAR) T-cell technology. In addition, I aim to test if this potential therapy could be used to treat other T-cell malignancies, and I hope to learn more about the maturation of healthy T-cells in the process.

CAR T-cells against T-cell malignancies
CAR T-cells are a new form of immune therapy, produced from one type of the patient’s own white blood cells (T-cells). These cells are genetically modified in the lab so that they can recognize and kill other cells based on specific molecules on the target cell’s surface. This has been a very effective new treatment for other types of leukemia (B-cell ALL, or B-ALL), but unfortunately the road towards an effective CAR T-cell product against malignant T-cells is not straightforward:

1. CAR T-cells are T-cells, just like the malignant T-cells we are trying to target. Therefore, if CAR T-cells are made to recognize all T-cells, they will also recognize and kill each other in a process called “fratricide”.

2. The successful existing CAR T-cell therapies against CD19+ B-ALL is not specific for tumor cells only. It generally recognized all B-cells, including the tumor cells, and leaves the patient without B-cells altogether. Although this is survivable and can be overcome by periodical antibody transfusions, complete loss of T-cells is not survivable. Therefore, a successful CAR T-cell treatment against T-cell malignancies needs to be tumor-specific, or the patient will need a bone marrow transplant to replace the lost T-cells. A bone marrow transplant is not without risks either.

3. The molecular targets we find on malignant T-cells cannot be expressed anywhere else on healthy cells in the body. As CAR T-cells will kill anything they can recognize, they can potentially cause severe side-effects if they also recognize the patient’s healthy tissues.

To avoid these various pitfalls, we need to identify novel molecular targets expressed only on leukemic T-cells with no or limited expression in healthy tissues. However, searching through all the proteins expressed by T-ALL cells to find a tumor-specific molecule using traditional techniques is like looking for a needle in a haystack. Therefore, I am developing a method to use cell surface proteomics. This method compares to sifting through a haystack using a big magnet. We don’t need to look at all the hay, only at everything that is magnetic.

Based on the targets we find using surface proteomics, I aim to develop new T-ALL CAR T-cell therapies. The effectiveness of these new CAR T-cell therapies will need to be validated, and then we need to figure out if we can make these cells from the few healthy T-cells that T-ALL patients have left.